Alban V.
- Country
- France
- Department
- Hematology Department
Research Overview
- Efficacy of Venetoclax Plus Cytarabine Versus Idarubicin Plus Cytarabine in Post-Remission Therapy for Elderly Patients with Acute Myeloid Leukemia
- An ALFA 2101 multicenter randomized phase II study: CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics
- Comparison of ATG-Thymoglobulin Versus ATLG-Grafalon for GVHD Prophylaxis in Elderly AML or MDS Patients Undergoing Allogeneic HSCT with Reduced Intensity Conditioning
Data & Insights
Has run more than one trial at 41 of 69 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating acute myeloid leukemia (AML), with particular focus on developing therapeutic strategies for different patient populations, including elderly patients and those with specific genetic mutations.
- FLT3-mutated AML treatment approaches
- Elderly-specific AML therapies
- Genomics-guided treatment selection
The research encompasses evaluation of novel drug combinations and treatment platforms for various AML subtypes.
Stem Cell Transplantation
The investigator conducts research in allogeneic hematopoietic stem cell transplantation, focusing on improving patient outcomes and managing transplant-related complications.
- Infection prevention strategies
- Transplant-related complications
- Supportive care measures
Their work includes developing preventive approaches for transplant-associated infections and optimizing patient care protocols.
Treatment Innovation
The investigator explores innovative therapeutic combinations including targeted therapies and novel drug formulations for hematologic conditions.
- Novel drug combinations
- Response assessment methods
- Risk-stratified approaches
Their research includes evaluation of treatment efficacy using sophisticated monitoring techniques such as minimal residual disease assessment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.